In Italy up to now 6,135 Covid patients have been treated with monoclonal antibodies, and entered in the special monitoring register created by the Italian Medicines Agency (Aifa). From 10 March, when these medicines were authorized as an emergency in Italy for particularly fragile people with recent Sars-CoV-2 infection and without severe symptoms, to 1 July, the date of the latest Aifa update, 195 facilities have been 21 Regions or autonomous provinces that have prescribed these therapies.
Treatments whose use shows a decreasing trend: in the week from 25 June to 1 July – the subject of the report – 34 prescriptions were carried out, compared to 57 in the previous 7 days (-40%), with a daily average of 4.86 against 8.14 of the previous week (-40.4%). Compared to the resident population, one dose was prescribed for every million inhabitants in the last week monitored.
From the start of monitoring, in absolute numbers Lazio remains the region with the greatest use with 832 patients treated, followed by Veneto with 789 patients and Tuscany with 746, while in the last places there are Molise and the Autonomous Province of Bolzano, respectively with 13 and 3 patients entered in the registry. To date, the majority of treated patients (3,424) have received the combination of the two antibodies bamlanivimab and etesevimab.